303 results on '"Mitlak, Bruce"'
Search Results
2. Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
3. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project
4. Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
5. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
6. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
7. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis
8. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption
9. Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study.
10. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe
11. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study
12. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
13. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
14. Pharmaceutical Treatments of Osteoporosis
15. List of Contributors
16. Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend
17. Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
18. The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial
19. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial
20. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
21. Femoral strength in osteoporotic women treated with teriparatide or alendronate
22. Bone mineral measurements by DXA in animals
23. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project
24. Quality of Life in Sarcopenia and Frailty
25. Pharmaceutical Treatments of Osteoporosis
26. List of Contributors
27. Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis
28. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
29. Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice
30. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men
31. Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
32. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis
33. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project.
34. Selective Estrogen Receptor Modulators: A Look Ahead
35. Regulatory Considerations for the Design and Conduct of Osteoporosis Registration Trials
36. Contributors
37. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
38. Chapter 21 - Pharmaceutical Treatments of Osteoporosis
39. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
40. Abstract #796012: Phase 1B Evaluation of the Pharmacokinetics and Pharmacodynamics of Abaloparatide Solid Microstructured Transdermal System in Postmenopausal Women with Low Bone Mineral Density
41. Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
42. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
43. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial
44. Teriparatide and Raloxifene Reduce the Risk of New Adjacent Vertebral Fractures in Postmenopausal Women with Osteoporosis: Results from Two Randomized Controlled Trials
45. Raloxifene and Risk for Stroke Based on the Framingham Stroke Risk Score
46. Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair
47. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
48. ENHANCEMENT OF EXPERIMENTAL FRACTURE-HEALING BY SYSTEMIC ADMINISTRATION OF RECOMBINANT HUMAN PARATHYROID HORMONE (PTH 1–34)
49. Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis
50. Pharmacogenomics in Endocrinology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.